A novel variant of human vascular endothelial growth factor (h’VEGF165) cDNA was amplified by nested PCR method from the HL60¹ cells and was cloned into a eukaryotic expressing vector pcDNA₃ to construct a recombinant plasmid pCD-h’VEGF165. The amplified h’VEGF165 cDNA fragment was identified by enzyme digestion and DNA sequencing methods. Also, wild-type hVEGF165 cDNA was obtained, identified and cloned into a eukaryotic expressing vector pcDNA3 by using the same methods. The results of DNA sequencing showed that h’VEGF165 cDNA cloned from HL60¹ was 600 bp in size with 8 % of the base sequence in h’VEGF165 cDNA being changed as compared with the base sequence in the wild-type hVEGF165 cDNA. The results of sequencing of hVEGF165 which was cloned from HL60 by us were consistent with the reports completely.

To investigate the serum substantia nigra neuron autoantibody and its effect in the patients with Parkinson disease (PD), substantia nigra slices and a rat model of injection of serum from PD patients in unilateral side substantia nigra were applied. The results showed that the positive rate of substantia nigra neuron autoantibody in PD patients was significantly higher than in the healthy control group (36. 67 % vs 6. 67 %,P<0. 01), but no significant difference was found between PD group and myasthenia gravis (MG) group (26. 67 %,P>0. 05). The sera from PD patients positive for substantia nigra neuron autoantibody could decrease the number of the dopaminergic neurons more seriously than those from MG and the healthy once respectively (bothP<0. 01). The results suggested that the immunological mechanism might partly play a role in the development of PD.